GlassScriptPhysician profile
Edward A Rico
NPI 1477739423
$134,766.91
in general payments reported to CMS, 2019-2025
34 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $22K · 2021: $17K · 2022: $24K · 2023: $540 · 2024: $260 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $807 · Education: $95.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.44 |
| Education | $95.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $84,231.17 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $20,293.11 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $14,497.67 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $12,989.30 | 2019-2022 | |
| Lilly USA, LLC | $395.69 | 2019-2024 | Mounjaro, Jardiance |
| Medtronic, INC. | $224.25 | 2021-2024 | Signia, Minimed 780g |
| Abbott Laboratories | $213.69 | 2020-2025 | Freestyle Libre 3 |
| Insulet Corporation | $204.56 | 2019-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.90 | 2020-2023 | Jardiance |
| Mannkind Corporation | $179.85 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $169.84 | 2020-2023 | Gvoke Hypopen |
| Abbvie INC. | $115.92 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $114.45 | 2019-2022 | |
| Amgen INC. | $102.40 | 2019-2025 | Tepezza |
| Corcept Therapeutics | $102.12 | 2020-2023 | Korlym |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $74.24 | 2019-2022 | |
| Ibsa Pharma INC. | $71.93 | 2020-2023 | Tirosint, Licart |
| Clarus Therapeutics INC. | $69.77 | 2021 | |
| Dexcom, INC. | $63.46 | 2021-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $62.59 | 2021 | |
| Horizon Therapeutics Plc | $61.39 | 2022-2023 | Tepezza |
| Tandem Diabetes Care, INC. | $59.10 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $48.52 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $45.43 | 2020-2023 | |
| Esperion Therapeutics, INC. | $32.86 | 2021-2023 | Nexletol |
| Amryt Pharma Holdings LTD | $19.73 | 2022 | |
| Amarin Pharma, INC. | $17.88 | 2019 | |
| Echosens North America, INC. | $17.66 | 2023 | Fibroscan |
| Kyowa Kirin, INC. | $17.45 | 2023 | Crysvita |
| Bayer Healthcare Pharmaceuticals INC. | $16.87 | 2022 | |
| Amneal Pharmaceuticals LLC | $16.57 | 2021 | |
| Medtronic Minimed, INC. | $13.77 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.09 | 2020 | |
| Zealand Pharma US, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Rico listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.